Aspire Biopharma
ASBP
56 hedge funds and large institutions have $267M invested in Aspire Biopharma in 2022 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 7 closing their positions.
2% more capital invested
Capital invested by funds: $261M → $267M (+$6.21M)
0% more ownership
Funds ownership: 0.07% → 0.08% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
5% less funds holding
Funds holding: 59 → 56 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
Radcliffe Capital Management
Bala Cynwyd,
Pennsylvania
|
+$3.47M |
| 2 |
LP
LMR Partners
London,
United Kingdom
|
+$2.55M |
| 3 |
AC
Aristeia Capital
Greenwich,
Connecticut
|
+$1.85M |
| 4 |
GCL
Glazer Capital LLC
New York
|
+$1.15M |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$894K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$6.79M |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
-$1.44M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$563K |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$507K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$497K |
ASBP Hedge Fund Activity: Q4 2022 in Review
56 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Aspire Biopharma (ASBP) for Q4 2022, worth a combined $267M — up 2.4% from $261M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ASBP and 4 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Radcliffe Capital Management, adding an estimated $3.47M. The largest seller was Highbridge Capital Management, cutting an estimated $6.79M.
- 56 institutional investors held Aspire Biopharma (ASBP) as of Q4 2022, down from 59 in Q3 2022.
- Funds reported $267M of Aspire Biopharma stock for Q4 2022, up 2.4% quarter-over-quarter.
- 4 funds opened new Aspire Biopharma positions in Q4 2022 and 7 closed out, a net change of -3 holders.
- The largest Aspire Biopharma buyer in Q4 2022 was Radcliffe Capital Management, an estimated $3.47M added.
- The largest Aspire Biopharma seller in Q4 2022 was Highbridge Capital Management, an estimated $6.79M sold.
Based on aggregated 13F filings for Q4 2022.